|
Blood
Many new drugs for the treatment of acute myeloid leukemia have emerged over the past 2 years. DiNardo and Wei use 3 cases to... [Read more]
Courtney D. Di Nardo, Andrew H. Wei
|
|
|
|
|
|
The Lancet
Maria-Victoria Mateos, MD et al.
|
|
|
|
|
CA: A Cancer Journal for Clinicians
|
|
|
|
|
Many new drugs for the treatment of acute myeloid leukemia have emerged over the past 2 years. DiNardo and Wei use 3 cases to illustrate how availability of these new agents is driving a reappraisal of the treatment decision-making process and providing a practical guide for choosing appropriate tailored therapies.
CLINICAL TRIALS AND OBSERVATIONS
Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trialJoseph Pidala,Mehdi Hamadani,Peter Dawson,Michael Martens,Amin M. Alousi,Madan Jagasia,Yvonne A. Efebera,Saurabh Chhabra,Iskra Pusic,Shernan G. Holtan,James L. M. Ferrara,John E. Levine,Marco Mielcarek,Claudio Anasetti,Joseph H. Antin,Javier Bolaños-Meade,Alan Howard,Brent R. Logan,Eric S. Leifer,Theresa S. Pritchard,Mary M. Horowitz,Margaret L. MacMillan
Steroids are conventional frontline therapy for acute graft-versus-host disease (GVHD) but induce substantial toxicity. This randomized multicenter comparison of sirolimus vs prednisone for treatment of standard-risk acute GVHD demonstrates similar response rates at 28 days. Sirolimus therapy was associated with reduced steroid use and improved quality of life.
LYMPHOID NEOPLASIA
Coactivation of NF-κB and Notch signaling is sufficient to induce B-cell transformation and enables B-myeloid conversion
Yan Xiu,Qianze Dong,Lin Fu,Aaron Bossler,Xiaobing Tang,Brendan Boyce,Nicholas Borcherding,Mariah Leidinger,José Luis Sardina,Hai-hui Xue,Qingchang Li,Andrew Feldman,Iannis Aifantis,Francesco Boccalatte,Lili Wang,Meiling Jin,Joseph Khoury,Wei Wang,Shimin Hu,Youzhong Yuan,Endi Wang,Ji Yuan,Siegfried Janz,John Colgan,Hasem Habelhah,Thomas Waldschmidt,Markus Müschen,Adam Bagg,Benjamin Darbro,Chen Zhao
The authors investigate the effect of combined activated NF-κB and Notch signaling, a combination that has been observed in subsets of B-cell lymphoma. They demonstrate in a mouse model that the combined activation induces lymphoma and further links the combination to secondary myeloid leukemia, a rare but observed phenomenon arising in patients with lymphoma.
Targeting chronic NFAT activation with calcineurin inhibitors in diffuse large B-cell lymphoma Philip Bucher,Tabea Erdmann,Paula Grondona,Wendan Xu,Anja Schmitt,Christoph Schürch,Myroslav Zapukhlyak,Caroline Schönfeld,Edgar Serfling,Daniela Kramer,Michael Grau,Pavel Klener,Claudia Lengerke,Klaus Schulze-Osthoff,Georg Lenz,Stephan Hailfinger
Activated B-cell–like diffuse large B-cell lymphoma (ABC-DLBCL) is more aggressive than its germinal center B-cell–like counterpart. Bucher et al demonstrate that DLBCL displays calcineurin-dependent constitutive NFAT activation and, in preclinical models, calcineurin inhibitors are uniquely toxic to ABC-DLBCL.
A role for NFAT signaling in ABC-DLBCL
Jagan R. Muppidi
MYELOID NEOPLASIA
Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms
Christian A. Di Buduo,Vittorio Abbonante,Caroline Marty,Francesco Moccia,Elisa Rumi,Daniela Pietra,Paolo M. Soprano,Dmitry Lim,Daniele Cattaneo,Alessandra Iurlo,Umberto Gianelli,Giovanni Barosi,Vittorio Rosti,Isabelle Plo,Mario Cazzola,Alessandra Balduini
About 25% of myeloproliferative neoplasms are caused by mutant calreticulin (CALR), which has been demonstrated to stimulate megakaryocyte proliferation by ligand-independent binding to the thrombopoietin receptor. Di Buduo and colleagues report that mutant CALR also shows loss of binding to calcium-regulatory proteins, leading to constitutive increase in intracellular calcium, further increasing proliferation of megakaryocytes, and contributing to their prominence as a clinical feature.
Both sides now: losses and gains of mutant CALR
Ann Mullally
Factor XIII (FXIII) stabilizes the fibrin clot and circulates as a tetramer. The authors identify the critical residues for interaction of FXIII subunits, mutations in which have been reported to be associated with congenital FXIII deficiency.
|
|
STIMULUS REPORT
Platelet α-granules contribute to organ-specific pathologies in a mouse model of severe malaria
Thayer K. Darling, Michael P. Schenk, Chengjing C. Zhou, Franklin M. Maloba, Patrice N. Mimche, Jonathan M. Gibbins, Shawn M. Jobe, Tracey J. Lamb
Blood Adv December 2019, Vol.4, 1-8. doi: 10.1182/bloodadvances.2019000773
Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphoma
Tim M. Illidge, Elizabeth H. Phillips, Nicholas Counsell, Ruth Pettengell, Peter W. M. Johnson, Dominic J. Culligan, Bilyana Popova, Laura Clifton-Hadley, Andrew McMillan, Peter Hoskin, Sally F. Barrington, John Radford
Blood Adv January 2020, Vol.4, 203-206. doi: 10.1182/bloodadvances.2019001023
PLATELETS AND THROMBOPOIESIS
A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia
Hanny Al-Samkari, Rachel P. Rosovsky, Rebecca S. Karp Leaf, David B. Smith, Katayoon Goodarzi, Annemarie E. Fogerty, David B. Sykes, David J. Kuter
Blood Adv December 2019, Vol.4, 9-18. doi: 10.1182/bloodadvances.2019000868
Supramaximal calcium signaling triggers procoagulant platelet formation
Nima Abbasian, Sarah L. Millington-Burgess, Shirom Chabra, Jean-Daniel Malcor, Matthew T. Harper
Blood Adv January 2020, Vol.4, 154-164. doi: 10.1182/bloodadvances.2019000182
HEALTH SERVICES AND OUTCOMES
Assessment of health-related quality of life among adults hospitalized with sickle cell disease vaso-occlusive crisis
Kimberly S. Esham, Angie Mae Rodday, Hedy P. Smith, Farzad Noubary, Ruth Ann Weidner, Rachel J. Buchsbaum, Susan K. Parsons
Blood Adv December 2019, Vol.4, 19-27. doi: 10.1182/bloodadvances.2019000128
Lymphoid Neoplasia
Eμ and 3′RR transcriptional enhancers of the IgH locus cooperate to promote c-myc–induced mature B-cell lymphomas
Nour Ghazzaui, Hussein Issaoui, Mélissa Ferrad, Claire Carrion, Jeanne Cook-Moreau, Yves Denizot, François Boyer
Blood Adv January 2020, Vol.4, 28-39. doi: 10.1182/bloodadvances.2019000845
Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT
Talha Badar, Narendranath Epperla, Aniko Szabo, Steven Borson, John Vaughn, Gemlyn George, Neeraj Saini, Abdul Rashid Shah, Romil D. Patel, Sairah Ahmed, Nirav N. Shah, Amanda F. Cashen, Mehdi Hamadani, Timothy S. Fenske
Blood Adv January 2020, Vol.4, 47-54. doi: 10.1182/bloodadvances.2019000736
PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation
Matthew J. Frigault, Philippe Armand, Robert A. Redd, Erin Jeter, Reid W. Merryman, Kimberly C. Coleman, Alex F. Herrera, Parastoo Dahi, Yago Nieto, Ann S. LaCasce, David C. Fisher, Samuel Y. Ng, Oreife O. Odejide, Arnold S. Freedman, Austin I. Kim, Jennifer L. Crombie, Caron A. Jacobson, Eric D. Jacobsen, Jeffrey L. Wong, Jad Bsat, Sanjay S. Patel, Jerome Ritz, Scott J. Rodig, Margaret A. Shipp, Yi-Bin Chen, Robin M. Joyce
Blood Adv January 2020, Vol.4, 122-126. doi: 10.1182/bloodadvances.2019000784
Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas
Xia Liu, Jiaji G. Chen, Manit Munshi, Zachary R. Hunter, Lian Xu, Amanda Kofides, Nickolas Tsakmaklis, Maria G. Demos, Maria Luisa Guerrera, Gloria G. Chan, Cristina Jimenez, Christopher J. Patterson, Kirsten Meid, Andrew Keezer, Jorge J. Castillo, Steven P. Treon, Guang Yang
Blood Adv January 2020, Vol.4, 141-153. doi: 10.1182/bloodadvances.2019000947
Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months
Thomas E. Lew, Mary Ann Anderson, Victor S. Lin, Sasanka M. Handunnetti, Neil A. Came, Piers Blombery, David A. Westerman, Meaghan Wall, Constantine S. Tam, Andrew W. Roberts, John F. Seymour
Blood Adv January 2020, Vol.4, 165-173. doi: 10.1182/bloodadvances.2019000864
TRANSPLANTATION
Refined National Institutes of Health response algorithm for chronic graft-versus-host disease in joints and fascia
Yoshihiro Inamoto, Stephanie J. Lee, Lynn E. Onstad, Mary E. D. Flowers, Betty K. Hamilton, Madan H. Jagasia, Paul J. Martin, Steven Z. Pavletic, Joseph A. Pidala, Iskra Pusic, Georgia B. Vogelsang, Daniel Wolff, Paul A. Carpenter
Blood Adv January 2020, Vol.4, 40-46. doi: 10.1182/bloodadvances.2019000918
Robust CD4+ T-cell recovery in adults transplanted with cord blood and no antithymocyte globulin
Ioannis Politikos, Jessica A. Lavery, Patrick Hilden, Christina Cho, Taylor Borrill, Molly A. Maloy, Sergio A. Giralt, Marcel R. M. van den Brink, Miguel-Angel Perales, Juliet N. Barker
Blood Adv January 2020, Vol.4, 191-202. doi: 10.1182/bloodadvances.2019000836
GENE THERAPY
The severe spontaneous bleeding phenotype in a novel hemophilia A rat model is rescued by platelet FVIII expression
Qizhen Shi, Jeremy G. Mattson, Scot A. Fahs, Aron M. Geurts, Hartmut Weiler, Robert R. Montgomery
Blood Adv January 2020, Vol.4, 55-65. doi: 10.1182/bloodadvances.2019000944
MYELOID NEOPLASIA
Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11
Yuichi Ishikawa, for the Japan Adult Leukemia Study Group, Naomi Kawashima, for the Japan Adult Leukemia Study Group, Yoshiko Atsuta, for the Japan Adult Leukemia Study Group, Isamu Sugiura, for the Japan Adult Leukemia Study Group, Masashi Sawa, for the Japan Adult Leukemia Study Group, Nobuaki Dobashi, for the Japan Adult Leukemia Study Group, Hisayuki Yokoyama, for the Japan Adult Leukemia Study Group, Noriko Doki, for the Japan Adult Leukemia Study Group, Akihiro Tomita, for the Japan Adult Leukemia Study Group, Toru Kiguchi, for the Japan Adult Leukemia Study Group, Shiro Koh, for the Japan Adult Leukemia Study Group, Heiwa Kanamori, for the Japan Adult Leukemia Study Group, Noriyoshi Iriyama, for the Japan Adult Leukemia Study Group, Akio Kohno, for the Japan Adult Leukemia Study Group, Yukiyoshi Moriuchi, for the Japan Adult Leukemia Study Group, Noboru Asada, for the Japan Adult Leukemia Study Group, Daiki Hirano, for the Japan Adult Leukemia Study Group, Kazuto Togitani, for the Japan Adult Leukemia Study Group, Toru Sakura, for the Japan Adult Leukemia Study Group, Maki Hagihara, for the Japan Adult Leukemia Study Group, Tatsuki Tomikawa, for the Japan Adult Leukemia Study Group, Yasuhisa Yokoyama, for the Japan Adult Leukemia Study Group, Norio Asou, for the Japan Adult Leukemia Study Group, Shigeki Ohtake, for the Japan Adult Leukemia Study Group, Itaru Matsumura, for the Japan Adult Leukemia Study Group, Yasushi Miyazaki, for the Japan Adult Leukemia Study Group, Tomoki Naoe, for the Japan Adult Leukemia Study Group, Hitoshi Kiyoi, for the Japan Adult Leukemia Study Group
Blood Adv January 2020, Vol.4, 66-75. doi: 10.1182/bloodadvances.2019000709
Circulating CD1c+ myeloid dendritic cells are potential precursors to LCH lesion CD1a+CD207+ cells
Karen Phaik Har Lim, Paul Milne, Michael Poidinger, Kaibo Duan, Howard Lin, Naomi McGovern, Harshal Abhyankar, Daniel Zinn, Thomas M. Burke, Olive S. Eckstein, Rikhia Chakraborty, Amel Sengal, Brooks Scull, Evan Newell, Miriam Merad, Kenneth L. McClain, Tsz-Kwong Man, Florent Ginhoux, Matthew Collin, Carl E. Allen
Blood Adv January 2020, Vol.4, 87-99. doi: 10.1182/bloodadvances.2019000488
THROMBOSIS AND HEMOSTASIS
GRK6 regulates the hemostatic response to injury through its rate-limiting effects on GPCR signaling in platelets
Xi Chen, Shuchi Gupta, Matthew Cooper, Daniel DeHelian, Xuefei Zhao, Meghna U. Naik, Jeremy G. T. Wurtzel, Timothy J. Stalker, Lawrence E. Goldfinger, Jeffrey Benovic, Lawrence F. Brass, Steven E. McKenzie, Ulhas P. Naik, Peisong Ma
Blood Adv January 2020, Vol.4, 76-86. doi: 10.1182/bloodadvances.2019000467
Low VWF levels in children and lack of association with bleeding in children undergoing tonsillectomy
Joan Cox Gill, Stephen F. Conley, Victoria P. Johnson, Pamela A. Christopherson, Sandra L. Haberichter, Christina D. Diaz, Tatyana C. Strong, Jian Zhang, Pippa Simpson, Thomas C. Abshire, Robert R. Montgomery, Veronica H. Flood
Blood Adv January 2020, Vol.4, 100-105. doi: 10.1182/bloodadvances.2019000992
MRI predicts 5-year joint bleeding and development of arthropathy on radiographs in hemophilia
Wouter Foppen, Irene C. van der Schaaf, Frederik J. A. Beek, Willem P. T. M. Mali, Kathelijn Fischer
Blood Adv January 2020, Vol.4, 113-121. doi: 10.1182/bloodadvances.2019001238
Metabolic syndrome increases risk of venous thromboembolism recurrence after acute deep vein thrombosis
Lauren K. Stewart, Jeffrey A. Kline
Blood Adv January 2020, Vol.4, 127-135. doi: 10.1182/bloodadvances.2019000561
von Willebrand factor binding to myosin assists in coagulation
Veronica H. Flood, Tricia L. Slobodianuk, Daniel Keesler, Hannah K. Lohmeier, Scot Fahs, Liyun Zhang, Pippa Simpson, Robert R. Montgomery
Blood Adv January 2020, Vol.4, 174-180. doi: 10.1182/bloodadvances.2019000533
Differential roles of factors IX and XI in murine placenta and hemostasis under conditions of low tissue factor
Steven P. Grover, Clare M. Schmedes, Alyson C. Auriemma, Emily Butler, Molly L. Parrish, Adam Miszta, Audrey C. Cleuren, Mayken Visser, Stefan Heitmeier, Jens J. Posma, Henri M. Spronk, Silvio Antoniak, Alisa S. Wolberg, Rafal Pawlinski, David Gailani, Nigel Mackman
Blood Adv January 2020, Vol.4, 207-216. doi: 10.1182/bloodadvances.2019000921
EXCEPTIONAL CASE REPORT
Clinical response to larotrectinib in adult Philadelphia chromosome–like ALL with cryptic ETV6-NTRK3 rearrangement
Valentina Nardi, Nora Ku, Matthew J. Frigault, Adrian M. Dubuc, Harrison Kwei Tsai, Philip C. Amrein, Gabriela S. Hobbs, Andrew M. Brunner, Rupa Narayan, Meghan E. Burke, Julia Foster, Paola Dal Cin, Marcela V. Maus, Amir T. Fathi, Hanno Hock
Blood Adv January 2020, Vol.4, 106-111. doi: 10.1182/bloodadvances.2019000769
ERRATUM
Goldmann L, Duan R, Kragh T, et al. Oral Bruton tyrosine kinase inhibitors block activation of the platelet Fc receptor CD32a (FcγRIIA): a new option in HIT? Blood Adv. 2019;3(23):4021-4033.
Blood Adv January 2020, Vol.4, 112. doi: 10.1182/bloodadvances.2019001362
CLINICAL TRIALS AND OBSERVATIONS
Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma
Armando Santoro, Rita Mazza, Alessandro Pulsoni, Alessandro Re, Maurizio Bonfichi, Vittorio Ruggero Zilioli, Manuela Zanni, Francesco Merli, Antonella Anastasia, Stefano Luminari, Giorgia Annechini, Manuel Gotti, Annalisa Peli, Anna Marina Liberati, Nicola Di Renzo, Luca Castagna, Laura Giordano, Francesca Ricci, Carmelo Carlo-Stella
Blood Adv January 2020, Vol.4, 136-140. doi: 10.1182/bloodadvances.2019000984
A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry
Zhaohui Du, Niels Weinhold, Gregory Chi Song, Kristin A. Rand, David J. Van Den Berg, Amie E. Hwang, Xin Sheng, Victor Hom, Sikander Ailawadhi, Ajay K. Nooka, Seema Singhal, Karen Pawlish, Edward S. Peters, Cathryn Bock, Ann Mohrbacher, Alexander Stram, Sonja I. Berndt, William J. Blot, Graham Casey, Victoria L. Stevens, Rick Kittles, Phyllis J. Goodman, W. Ryan Diver, Anselm Hennis, Barbara Nemesure, Eric A. Klein, Benjamin A. Rybicki, Janet L. Stanford, John S. Witte, Lisa Signorello, Esther M. John, Leslie Bernstein, Antoinette M. Stroup, Owen W. Stephens, Maurizio Zangari, Frits Van Rhee, Andrew Olshan, Wei Zheng, Jennifer J. Hu, Regina Ziegler, Sarah J. Nyante, Sue Ann Ingles, Michael F. Press, John David Carpten, Stephen J. Chanock, Jayesh Mehta, Graham A. Colditz, Jeffrey Wolf, Thomas G. Martin, Michael Tomasson, Mark A. Fiala, Howard Terebelo, Nalini Janakiraman, Laurence Kolonel, Kenneth C. Anderson, Loic Le Marchand, Daniel Auclair, Brian C.-H. Chiu, Elad Ziv, Daniel Stram, Ravi Vij, Leon Bernal-Mizrachi, Gareth J. Morgan, Jeffrey A. Zonder, Carol Ann Huff, Sagar Lonial, Robert Z. Orlowski, David V. Conti, Christopher A. Haiman, Wendy Cozen
Blood Adv January 2020, Vol.4, 181-190. doi: 10.1182/bloodadvances.2019000491
BLOOD ADVANCES TALK
TA-TMA: state of the art for diagnosis and treatment
Christopher C. Dvorak
Blood Adv January 2020, Vol.4, 217. doi: 10.1182/bloodadvances.2019000321
TESTING ADVANCES
Clinical diagnostics and treatment strategies for Philadelphia chromosome–like acute lymphoblastic leukemia
Richard C. Harvey, Sarah K. Tasian
Blood Adv January 2020, Vol.4, 218-228. doi: 10.1182/bloodadvances.2019000163
REVIEW ARTICLE
An update on the molecular pathogenesis and potential therapeutic targeting of AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1
Sayer Al-Harbi, Mahmoud Aljurf, Mohamad Mohty, Fahad Almohareb, Syed Osman Ali Ahmed
Blood Adv January 2020, Vol.4, 229-238. doi: 10.1182/bloodadvances.2019000168 |
|
Venous thromboembolism risk with contemporary lenalidomide‐based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta‐analysis
Rajshekhar Chakraborty MD, MD, Irbaz Bin Riaz MBBS, MS, Saad Ullah Malik MD, Naimisha Marneni MD, Alex Mejia Garcia MD, Faiz Anwer MD, Alok A. Khorana MD, S. Vincent Rajkumar MD, Shaji Kumar MD, M. Hassan Murad MD, Zhen Wang PhD, Safi U. Khan MD, MS, Navneet S. Majhail MD, MS
Version of Record online: 08 January 2020
In this systematic review and meta‐analysis of 51 clinical trials, including 9069 patients with multiple myeloma, the cumulative incidence of venous thromboembolism with lenalidomide‐based regimens in patients with newly diagnosed and relapsed/refractory myeloma is 6.2%, with 1.2 events per 100 patient‐cycles. The incidence is higher using regimens incorporating proteasome inhibitors or anthracyclines compared with those using lenalidomide‐low dose dexamethasone.
When a randomized controlled trial is unlikely: Propensity score analysis of blinatumomab in adults with relapsed/refractory Philadelphia chromosome–positive B‐cell acute lymphoblastic leukemia
Ryan D. Cassaday MD
A randomized controlled trial of blinatumomab for the treatment of patients with Philadelphia chromosome–positive B‐cell acute lymphoblastic leukemia is unlikely. In this issue of Cancer, Rambaldi et al perform a propensity score analysis to provide a comparison with historical standards of care.
Replacing chemotherapy with arsenic trioxide for the treatment of acute promyelocytic leukemia in the frontline setting: Is it cost‐effective?
Umut Yilmaz MD, Ahmet Emre Eskazan MD
Pages: 256-259 | First Published: 12 November 2019
Arsenic trioxide (ATO) is highly effective for the treatment of patients with acute promyelocytic leukemia (APL). In their study, Chen et al analyze the financial impact of the use of ATO in the upfront treatment setting for patients with APL in China and report it to be cost‐effective, a finding that is consistent with previous studies conducted in the United States and Canada.
|
|
Impact of Genetics on Mature Lymphoid Leukemias and Lymphomas
Nathanael G. Bailey and Kojo S.J. Elenitoba-Johnson
Cold Spring Harb Perspect Med published 13 January 2020; doi:10.1101/cshperspect.a035444
http://perspectivesinmedicine.cshlp.org/content/early/2020/01/13/cshperspect.a035444.abstract
|
|
Factors Associated With Successful Discontinuation of Immune Suppression After Allogeneic Hematopoietic Cell Transplantation
Joseph Pidala, MD, PhD; Michael Martens, PhD; Claudio Anasetti, MD; et al.
Association of Anesthesia Care and Cognitive Outcomes in Survivors of Childhood Acute Lymphoblastic Leukemia
Sachi Ishida, MD; Norifumi Kuratani, MD, PhD, MPH
Association of Anesthesia Care and Cognitive Outcomes in Survivors of Childhood Acute Lymphoblastic Leukemia
Douglas A. Colquhoun, MB ChB, MSc, MPH; Michael R. Mathis, MD
Association of Anesthesia Care and Cognitive Outcomes in Survivors of Childhood Acute Lymphoblastic Leukemia—Reply
Kevin R. Krull, PhD; Ching-Hon Pui, MD
|
|
ViewEngraftment of rare, pathogenic donor hematopoietic mutations in unrelated hematopoietic stem cell transplantation
Wing Hing Wong , Sima Bhatt, Kathryn Trinkaus, Iskra Pusic, Kevin Elliott, Nitin Mahajan, Fei Wan, Galen E. Switzer, Dennis L. Confer, John DiPersio, Michael A. Pulsipher, Nirali N. Shah, Jennifer Sees, Amelia Bystry, Jamie R. Blundell, Bronwen E. Shaw, Todd E. Druley
|
|
High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model
Rebecca A. Luchtel, Tushar Bhagat, Kith Pradhan, William R. Jacobs Jr, Mark Levine, Amit Verma, and Niraj Shenoy
|
|
|
|
